Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Abeona Therapeutics Inc.

ABEO Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Abeona Therapeutics Inc. had $5.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’10.3% a year on average.

Add to portfolio Download report

Last close Β· Oct 23, 2026

$4.40

1.6%

What Abeona Therapeutics Inc. does

ABEO Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
ABEONA THERAPEUTICS INC.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 17, 2026
Accession Β· CIK
0001493152-26-010413 Β· 0000318306

Earnings calendar Β· Abeona Therapeutics Inc.

Every quarter, companies publish how much they sold and earned. These are the days Abeona Therapeutics Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 11, 2026

Wednesday Β· in 15 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.14
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 13, 2026 Q2 '26 Before the market opens 8-K β†—
May 13, 2026 Q1 '26 Before the market opens 8-K β†—
Mar 17, 2026 Q4 '25 Before the market opens 8-K β†—
Nov 12, 2025 Q3 '25 Before the market opens 8-K β†—
Aug 14, 2025 Q2 '25 Before the market opens 8-K β†—
May 15, 2025 Q1 '25 Before the market opens 8-K β†—
Mar 20, 2025 Q4 '24 Before the market opens 8-K β†—
Nov 14, 2024 Q3 '24 Before the market opens 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Abeona Therapeutics Inc.’s latest annual report (fiscal 2025). Here is what stands out:

2 strengths 2 to watch

1.Sales and profit

See section β†’
  • Abeona Therapeutics Inc. had $5.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’10.3% a year on average.
  • Its operating margin was βˆ’1,536.9%: of every 100 in sales, about βˆ’1,537 is left after running the business.
  • Abeona Therapeutics Inc. made $71.2M of net profit in fiscal 2025.

Abeona Therapeutics Inc. in 30 seconds

Good So-so Weak

Good

Does it make a profit?

1,223.1%

Yes. It keeps 1,223.1% of every sale as profit.

Weak

Does profit turn into cash?

βˆ’1,448.5%

No. It spent more cash than it brought in.

So-so

How healthy are the accounts?

4 / 7

Mixed. It passes 4 of 7 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$251M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$1.11 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Abeona Therapeutics Inc. had $5.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’10.3% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

KIRA Β· Its operating margin was βˆ’1,536.9%: of every 100 in sales, about βˆ’1,537 is left after running the business.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Abeona Therapeutics Inc. made $71.2M of net profit in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$84.3M in fiscal 2025, βˆ’1,448.5% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Abeona Therapeutics Inc. had $5.8M of revenue in fiscal 2025. Over five years, revenue changed βˆ’10.3% a year on average. Its operating margin was βˆ’1,536.9%: of every 100 in sales, about βˆ’1,537 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Abeona Therapeutics Inc. made $71.2M of net profit in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$84.3M in fiscal 2025, βˆ’1,448.5% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders sold $3.6M of shares on the open market and bought none.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$3.6M

9 insiders

Of sales under plans

19%

$0.7M

DateInsiderTradeSharesPriceValueFiling
Sep 29, 2026 Vishwas SeshadriChief Executive Officer, Director Sold 19,608 $5.16 $0.1M Form 4
Sep 29, 2026 Madhav VasanthavadaChief Commercial Officer Sold 4,902 $5.16 $0.0M Form 4
Sep 29, 2026 Joseph Walter VazzanoChief Financial Officer Sold 9,191 $5.16 $0.0M Form 4
Sep 29, 2026 Brendan M. O'MalleySVP, Chief Legal Officer Sold 6,727 $5.16 $0.0M Form 4
Sep 1, 2026 Mark AlvinoDirector Sold 15,000 $5.86 $0.1M Form 4
Jul 21, 2026 Joseph Walter VazzanoChief Financial Officer Sold 1,478 $6.53 $0.0M Form 4
Jul 9, 2026 Brendan M. O'MalleySVP, Chief Legal Officer Sold 12,050 $6.96 $0.1M Form 4
Jul 9, 2026 Madhav VasanthavadaChief Commercial Officer Sold 12,606 $6.96 $0.1M Form 4
Jul 9, 2026 Joseph Walter VazzanoChief Financial Officer Sold 24,880 $6.96 $0.2M Form 4
Jul 9, 2026 Vishwas SeshadriChief Executive Officer, Director Sold 67,971 $6.96 $0.5M Form 4
Jun 30, 2026 Leila AllandDirector Sold 11,000 $5.92 $0.1M Form 4
Jun 15, 2026 Christine Berni SilversteinDirector Sold 18,160 $5.71 $0.1M Form 4
Jun 9, 2026 Madhav VasanthavadaChief Commercial Officer Sold 5,450 $5.30 $0.0M Form 4
Jun 9, 2026 Vishwas SeshadriChief Executive Officer, Director Sold 31,916 $5.30 $0.2M Form 4
Jun 9, 2026 Joseph Walter VazzanoChief Financial Officer Sold plan 39,067 $5.36 $0.2M Form 4
Jun 9, 2026 Brendan M. O'MalleySVP, Chief Legal Officer Sold 6,305 $5.30 $0.0M Form 4
Jun 8, 2026 Brendan M. O'MalleySVP, Chief Legal Officer Sold 4,826 $5.43 $0.0M Form 4
Jun 8, 2026 Madhav VasanthavadaChief Commercial Officer Sold 4,170 $5.43 $0.0M Form 4
Jun 8, 2026 Vishwas SeshadriChief Executive Officer, Director Sold 24,428 $5.43 $0.1M Form 4
Jun 8, 2026 Joseph Walter VazzanoChief Financial Officer Sold plan 10,271 $5.43 $0.1M Form 4
May 22, 2026 Mark AlvinoDirector Sold 6,500 $5.46 $0.0M Form 4
May 15, 2026 Eric CrombezDirector Sold plan 26,143 $5.53 $0.1M Form 4
May 11, 2026 Madhav VasanthavadaChief Commercial Officer Sold 5,548 $5.96 $0.0M Form 4
Mar 31, 2026 Vishwas SeshadriChief Executive Officer, Director Sold plan 29,985 $4.38 $0.1M Form 4
Mar 16, 2026 Joseph Walter VazzanoChief Financial Officer Sold 785 $4.76 $0.0M Form 4
Feb 2, 2026 Mark AlvinoDirector Sold 2,000 $5.09 $0.0M Form 4
Feb 2, 2026 Christine Berni SilversteinDirector Sold 20,070 $5.09 $0.1M Form 4
Feb 2, 2026 Leila AllandDirector Sold 18,065 $5.09 $0.1M Form 4
Feb 2, 2026 Eric CrombezDirector Sold 16,284 $5.09 $0.1M Form 4
Feb 2, 2026 Donald A. WuchterlDirector Sold 14,814 $5.09 $0.1M Form 4
Jan 22, 2026 Vishwas SeshadriChief Executive Officer, Director Sold 69,832 $5.33 $0.4M Form 4
Jan 22, 2026 Madhav VasanthavadaChief Commercial Officer Sold 12,610 $5.29 $0.1M Form 4
Jan 22, 2026 Joseph Walter VazzanoChief Financial Officer Sold 18,666 $5.33 $0.1M Form 4
Jan 22, 2026 Brendan M. O'MalleySVP, Chief Legal Officer Sold 13,578 $5.33 $0.1M Form 4
Jan 21, 2026 Mark AlvinoDirector Sold 13,500 $5.23 $0.1M Form 4
Dec 29, 2025 Vishwas SeshadriChief Executive Officer, Director Sold plan 25,000 $5.31 $0.1M Form 4
Nov 13, 2025 Mark AlvinoDirector Sold 15,000 $4.74 $0.1M Form 4
Oct 16, 2025 Vishwas SeshadriChief Executive Officer, Director Sold 249 $5.49 $0.0M Form 4
Sep 30, 2025 Vishwas SeshadriChief Executive Officer, Director Sold plan 25,000 $5.24 $0.1M Form 4
Sep 29, 2025 Vishwas SeshadriChief Executive Officer, Director Sold plan 19,274 $5.39 $0.1M Form 4
Sep 29, 2025 Brendan M. O'MalleySVP, Chief Legal Officer Sold 9,366 $5.39 $0.1M Form 4
Sep 29, 2025 Joseph Walter VazzanoChief Financial Officer Sold 9,035 $5.39 $0.0M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Abeona Therapeutics Inc. has $171M more cash than debt.

Cash, debt and the ratios that show how comfortably Abeona Therapeutics Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $45.0M$52.1M$52.2M$97.7M$191M
Debt incl. finance leases β€”β€”β€”$19.0M$20.0M
Debt / equity β€”β€”β€”0.4x0.1x
Interest coverage βˆ’24.6xβˆ’69.2xβˆ’112.8xβˆ’15.3xβˆ’23.9x
Current ratio 3.4x6.8x4.2x6.1x6.9x
Quick ratio 3.4x6.8x4.2x6.1x6.7x
Total assets $79.6M$64.2M$64.0M$109M$220M
Total liabilities $37.2M$37.5M$49.2M$64.9M$60.4M
Shareholders' equity $42.4M$26.8M$14.8M$44.0M$159M
Net debt (βˆ’ = net cash) β€”β€”β€”βˆ’$78.8Mβˆ’$171M

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Abeona Therapeutics Inc. passes 4 of 7 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ“
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ• βœ• βœ• βœ• βœ“ βœ• βœ“ βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ•
Debt fell relative to assets β€” β€” β€” β€” β€” β€” β€” β€” β€” βœ“
Current ratio rose β€” βœ“ βœ• βœ• βœ• βœ“ βœ“ βœ• βœ“ βœ“
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ“ βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” βœ• βœ“ β€” β€” βœ• βœ• βœ“ β€” β€”
F-score β€” / 33 / 72 / 7β€” / 6β€” / 62 / 73 / 72 / 7β€” / 64 / 7
Accruals ratio βˆ’8.0%βˆ’3.2%βˆ’9.9%βˆ’6.8%βˆ’26.3%βˆ’16.7%5.3%βˆ’26.8%βˆ’8.9%89.8%
Altman Z'' 1.1117.95βˆ’3.84βˆ’2.50βˆ’11.29βˆ’29.98βˆ’35.25βˆ’38.47βˆ’22.51βˆ’5.75

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $0.9M $0.8M $3.0M β€” $10.0M $3.0M $1.4M $3.5M β€” $5.8M
Gross profit β€” β€” β€” β€” β€” β€” β€” β€” β€” $4.3M
Research and development $10.7M $17.0M $38.7M $48.6M $30.1M $38.7M $29.0M $31.1M $34.4M $26.8M
Operating income βˆ’$23.9M βˆ’$27.8M βˆ’$58.2M βˆ’$77.1M βˆ’$81.4M βˆ’$89.8M βˆ’$50.9M βˆ’$47.1M βˆ’$64.2M βˆ’$89.4M
Interest expense β€” β€” β€” β€” $4.1M $3.7M $0.7M $0.4M $4.2M $3.7M
Pretax income β€” β€” β€” β€” β€” β€” β€” β€” βˆ’$63.7M $71.3M
Income tax $0.0M $0.0M $0.0M β€” β€” β€” β€” β€” β€” $0.1M
Net income βˆ’$21.9M βˆ’$27.3M βˆ’$56.7M βˆ’$76.3M βˆ’$84.2M βˆ’$84.9M βˆ’$39.7M βˆ’$54.2M βˆ’$63.7M $71.2M
Net income to common βˆ’$21.9M β€” β€” β€” β€” βˆ’$84.9M βˆ’$43.5M βˆ’$54.2M βˆ’$63.7M β€”
Diluted EPS βˆ’$0.64 βˆ’$0.66 βˆ’$1.19 βˆ’$1.51 βˆ’$0.91 βˆ’$0.86 βˆ’$5.53 βˆ’$2.53 βˆ’$1.55 $1.01
Diluted shares 0.03B 0.04B 0.05B 0.05B 0.09B 0.10B 0.01B 0.02B 0.04B 0.07B
Cash flow
Cash from operations βˆ’$13.0M βˆ’$22.7M βˆ’$39.1M βˆ’$62.8M βˆ’$35.0M βˆ’$65.7M βˆ’$43.5M βˆ’$37.0M βˆ’$56.0M βˆ’$76.3M
Capital expenditure $0.5M $0.9M $9.2M $6.3M $1.3M $4.2M $0.1M $0.3M $2.4M $8.0M
Free cash flow βˆ’$13.5M βˆ’$23.5M βˆ’$48.4M βˆ’$69.1M βˆ’$36.4M βˆ’$69.8M βˆ’$43.6M βˆ’$37.3M βˆ’$58.5M βˆ’$84.3M
Depreciation and amortization $0.8M $0.7M $2.4M $7.8M $4.6M $3.3M $3.1M $2.3M $2.0M $2.5M
Stock-based compensation $4.8M $4.6M $8.2M $7.3M $5.9M $8.9M $3.1M $4.8M $6.6M $10.8M
Balance sheet
Cash and short-term investments $69.1M $138M $85.0M $129M $95.0M $45.0M $52.1M $52.2M $97.7M $191M
Total debt β€” β€” β€” β€” β€” β€” β€” β€” $19.0M $20.0M
Current assets $69.4M $141M $88.9M $132M $97.7M $56.3M $53.1M $55.7M $101M $205M
Current liabilities $8.3M $5.6M $20.4M $38.7M $42.0M $16.6M $7.8M $13.4M $16.6M $29.6M
Inventory β€” β€” β€” β€” β€” β€” β€” β€” β€” $5.5M
Property and equipment, net $0.7M $1.4M $9.4M $13.2M $11.3M $12.3M $5.7M $3.5M $4.4M $9.9M
Goodwill $32.5M $32.5M $32.5M $32.5M $32.5M β€” β€” β€” β€” β€”
Intangible assets $8.4M $4.0M $43.0M $36.2M $1.5M $1.4M $0.0M β€” β€” β€”
Total assets $111M $179M $174M $223M $151M $79.6M $64.2M $64.0M $109M $220M
Total liabilities $12.0M $8.7M $40.4M $45.0M $48.6M $37.2M $37.5M $49.2M $64.9M $60.4M
Shareholders' equity $99.1M $170M $134M $178M $103M $42.4M $26.8M $14.8M $44.0M $159M
Margins
Gross margin β€” β€” β€” β€” β€” β€” β€” β€” β€” 73.7%
Operating margin βˆ’2,686.3% βˆ’3,325.7% βˆ’1,940.2% β€” βˆ’814.2% βˆ’2,994.5% βˆ’3,600.8% βˆ’1,346.7% β€” βˆ’1,536.9%
EBITDA margin βˆ’2,593.5% βˆ’3,237.2% βˆ’1,861.4% β€” βˆ’768.3% βˆ’2,886.2% βˆ’3,382.0% βˆ’1,281.3% β€” βˆ’1,493.1%
Net margin βˆ’2,460.4% βˆ’3,263.9% βˆ’1,890.3% β€” βˆ’842.3% βˆ’2,831.2% βˆ’2,807.4% βˆ’1,548.2% β€” 1,223.1%
FCF margin βˆ’1,522.3% βˆ’2,809.4% βˆ’1,612.9% β€” βˆ’363.6% βˆ’2,327.2% βˆ’3,084.4% βˆ’1,066.9% β€” βˆ’1,448.5%
Returns
Return on capital employed βˆ’23.2% βˆ’16.1% βˆ’37.8% βˆ’41.7% βˆ’74.5% βˆ’142.7% βˆ’90.2% βˆ’93.2% βˆ’69.5% βˆ’47.1%
Return on equity βˆ’22.1% βˆ’20.3% βˆ’37.3% βˆ’48.8% βˆ’60.0% βˆ’117.2% βˆ’114.8% βˆ’260.6% βˆ’216.6% 70.0%
Return on assets βˆ’19.7% βˆ’18.9% βˆ’32.1% βˆ’38.4% βˆ’45.0% βˆ’73.6% βˆ’55.2% βˆ’84.5% βˆ’73.7% 43.3%
Return on tangible equity βˆ’37.6% βˆ’20.4% βˆ’96.8% βˆ’69.5% βˆ’122.8% βˆ’207.2% βˆ’162.5% βˆ’365.6% βˆ’144.7% 44.7%
Growth
Revenue growth β€” βˆ’5.8% 258.2% β€” β€” βˆ’70.0% βˆ’52.9% 147.5% β€” β€”
Share count change β€” 21.8% 14.1% 5.9% 84.0% 6.2% βˆ’92.0% 172.0% 92.0% 61.1%
Financial health
Debt / equity β€” β€” β€” β€” β€” β€” β€” β€” 0.4x 0.1x
Interest coverage β€” β€” β€” β€” βˆ’19.8x βˆ’24.6x βˆ’69.2x βˆ’112.8x βˆ’15.3x βˆ’23.9x
Current ratio 8.4x 25.1x 4.4x 3.4x 2.3x 3.4x 6.8x 4.2x 6.1x 6.9x
Quick ratio 8.4x 25.1x 4.4x 3.4x 2.3x 3.4x 6.8x 4.2x 6.1x 6.7x
Capital allocation
Capex / revenue 58.4% 102.7% 308.3% β€” 13.4% 138.4% 9.2% 9.5% β€” 137.0%
Stock comp / revenue 543.2% 554.8% 272.8% β€” 58.5% 297.2% 215.8% 136.2% β€” 185.2%
Quality scores
Piotroski F-score β€” 3.0 2.0 β€” β€” 2.0 3.0 2.0 β€” 4.0
Altman Z'' 1.1 18.0 βˆ’3.8 βˆ’2.5 βˆ’11.3 βˆ’30.0 βˆ’35.2 βˆ’38.5 βˆ’22.5 βˆ’5.7
Accruals ratio βˆ’8.0% βˆ’3.2% βˆ’9.9% βˆ’6.8% βˆ’26.3% βˆ’16.7% 5.3% βˆ’26.8% βˆ’8.9% 89.8%

Source: SEC EDGAR XBRL filings (CIK 0000318306). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open